What Is GHRP-6? Benefits, Research & Safety
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
UK summary: Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.
Quick Facts
Overview
GHRP-6 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: GHRP-6 is not approved by any regulatory authority for therapeutic use. It is prohibited in sports by WADA. Available only as a research compound.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Stimulates GH safely for muscle gain and recovery.
- Boosts appetite for hardgainers without side effects.
- Safe for daily long-term cycling.
- Undetectable by drug tests.
07Common internet claims
- Marketed in bodybuilding stacks for bulking phases.
- Sold online as an appetite-stimulating GH secretagogue.
- Promoted as the original GHRP and 'cheaper than HGH'.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates appetite for muscle-building cycles” | D | Limited | High | Ghrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy. |
| “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus” | D | Limited | High | Short-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim. |
| “Safe long-term for healthy adults” | E | No | High | Long-term human safety in healthy adults is not established. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Intense appetite stimulation (defining effect; may be unwanted).
- Cortisol and prolactin elevation.
- Water retention, joint pain, carpal tunnel symptoms.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains GHRP-6 at the labelled concentration.
- Whether the hunger response represents real physiologic ghrelin activation or a contaminant.
- What chronic ghrelin-receptor activation does to metabolic and oncologic risk.
- WADA detection windows — assume positive on test, prohibition is strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- No Phase 3 trials for any indication in healthy adults.
- Long-term safety beyond a few months absent.
- Combination-stack safety uncharacterised.
- Cancer-surveillance data unavailable.
19Safer alternatives / established care pathways
- Endocrinologist review and formal GH-deficiency testing if clinically suspected.
- Licensed recombinant HGH under specialist supervision where confirmed.
- Calorie surplus, resistance training, and protein-adequate diet for body-composition goals.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-6 a licensed UK medicine?
- What's the WADA / UKAD position for athletes?
- What are the theoretical risks of chronic ghrelin-receptor activation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent stimulation of growth hormone release
- 2Elevated IGF-1 levels
- 3Significant appetite stimulation (beneficial for underweight individuals)
- 4Potential cardioprotective effects
- 5Possible improvements in body composition with proper nutrition
- 6Synergistic effects with GHRH analogues
Claim vs Evidence
How popular claims about GHRP-6 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates appetite for muscle-building cycles” | D | Limited | High | Ghrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy. |
| “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus” | D | Limited | High | Short-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim. |
| “Safe long-term for healthy adults” | E | No | High | Long-term human safety in healthy adults is not established. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-300 mcg per dose |
| Frequency | 2-3 times daily, typically before meals |
| Duration | Variable; often cycled |
| Notes | GHRP-6 is not approved for therapeutic use. Its strong appetite stimulation should be considered—it may not be appropriate for those trying to limit food intake. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
| Half-Life | Stability |
|---|---|
| Approximately 15-20 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Intense hunger (very common)
- Water retention
- Injection site reactions
- Flushing
- Tingling or numbness
- Transient cortisol elevation
Rare Risks & Concerns
- Effects on blood glucose
- Unknown long-term effects
- Potential issues with chronic cortisol elevation
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Diabetes (monitor closely)
- Eating disorders (appetite effects)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
This suggests that thyroid hormone excess interferes with GH-releasing pathways activated by these peptides. Our results also suggest that ghrelin's ability to increase glucose levels is not altered in thyrotoxicosis.
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
These data show that GH responses to GHRP-6 are much greater than to GHRH in late adulthood. The marked increase of plasma GH levels observed after administration of GHRP-6 alone or in combination with GHRH indicates that impaired GH secretion in late adulthood is a functional and potentially reversible state.
Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.
It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.
Water-in-oil microemulsions for effective transdermal delivery of proteins.
The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting.
Diagnosis of adult GH deficiency.
In adults cut-off levels of GH response below which severe GHD is demonstrated must be appropriate to lean, overweight and obese subjects to avoid false positive diagnosis in obese adults and false negative diagnosis in lean GHD patients.
Diagnosis of adult GH deficiency.
Overweight and obesity have confounding effect on the interpretation of the GH response to provocative tests. In adults cut-off levels of GH response below which severe GHD is demonstrated must be appropriate to lean, overweight and obese subjects to avoid false positive diagnosis in obese adults and false negative diagnosis in lean GHD patients.
Looking for GHRP-6?
Source research-grade GHRP-6 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GHRP-6
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-6 a licensed UK medicine?
- What's the WADA / UKAD position for athletes?
- What are the theoretical risks of chronic ghrelin-receptor activation?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreHexarelin
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
Learn more